“Dr.BP did do blood analysis on both CD10 and CD
Post# of 148277
(Total Views: 743)
Posted On: 07/05/2020 8:45:14 AM
“Dr.BP did do blood analysis on both CD10 and CD12 (@ ~55 minutes)
On this last point, and at the risk of appearing defensive, I made this assertion in my controversial post a couple of days ago.”
This is good news, for both general research purposes and for the trials as it’s another method in which CYDY can demonstrate that leronlimab is working.
You and otherA have insinuated that Dr. BP and his lab are tracking deaths in the placebo and control arm by noting when labs are discontinued for certain patients. Prior to this, though, Dr. BP and his lab would have to assume which patient is in which arm based on labs by looking for a response to leronlimab similar to that observed in the first 11 EIND patients. Could this be done? Sounds feasible. Would doing so take extra time? Yes. Do we know this is being done by Dr. BP and that Dr. BP is then passing the information to NP? No, but again, it’s plausible. Would this being considered a breach of a double blinded, placebo controlled trial approved by the FDA?
Honestly, we won’t know if this process is occurring unless NP comes out and says it, which I think would be a bad idea. At this point, it’s a 50/50 chance.
On this last point, and at the risk of appearing defensive, I made this assertion in my controversial post a couple of days ago.”
This is good news, for both general research purposes and for the trials as it’s another method in which CYDY can demonstrate that leronlimab is working.
You and otherA have insinuated that Dr. BP and his lab are tracking deaths in the placebo and control arm by noting when labs are discontinued for certain patients. Prior to this, though, Dr. BP and his lab would have to assume which patient is in which arm based on labs by looking for a response to leronlimab similar to that observed in the first 11 EIND patients. Could this be done? Sounds feasible. Would doing so take extra time? Yes. Do we know this is being done by Dr. BP and that Dr. BP is then passing the information to NP? No, but again, it’s plausible. Would this being considered a breach of a double blinded, placebo controlled trial approved by the FDA?
Honestly, we won’t know if this process is occurring unless NP comes out and says it, which I think would be a bad idea. At this point, it’s a 50/50 chance.
(2)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼